Aletho News

ΑΛΗΘΩΣ

CDC changes its messaging after I caught them out on their moneypox vaccine lies

By Meryl Nass, MD | August 1, 2022

Here are a few of the lies they have backed off:

1. As of July 28, CDC has ceased claiming the monkeypox vaccine(s) is 85% effective. It now admits it does not know its effectiveness.

2. CDC has stopped recommending the OFF LABEL use of moneypox vaccine post-exposure (even up to 14 days post-exposure was the recommendation earlier). They are now telling the truth, which is that the vaccine is only approved as a two dose series and it is licensed as effective only 2 weeks after the second dose, which is 6 weeks after starting the series. There is no data to support post-exposure prophylaxis, which is OFF LABEL use.

3. CDC finally admits that everyone getting vaccinated is a guinea pig in a big experiment.

4. However, CDC still OMITS what it knows about the dangers of these vaccines, information it provided to its advisory committee a mere month ago. ACAM 2000 vaccine causes myocarditis in one in every 175 recipients. And Jynneos seems to cause myocarditis too, as well as making HIV worse, according to the FDA review issued when the vaccines was licensed in 2019. We just don’t have the Jynneos statistics to say how often these problems occur, but in one study more than one in 6 subjects had elevation of cardiac enzymes, which requires some heart muscles cells to die.

Below is the new CDC messaging.

https://www.cdc.gov/poxvirus/monkeypox/considerations-for-monkeypox-vaccination.html

What You Need to Know
  • Two vaccines may be used for the prevention of Monkeypox virus infection:
    • JYNNEOS (also known as Imvamune or Imvanex), licensed (or approved) by the U.S. Food and Drug Administration (FDA) for the prevention of Monkeypox virus infection, and
    • ACAM2000, licensed (or approved) by FDA for use against smallpox and made available for use against monkeypox under an Expanded Access Investigational New Drug application.
  • In the United States, there is currently a limited supply of JYNNEOS, although more is expected in the coming weeks and months.
  • There is a larger supply of ACAM2000, but this vaccine should not be used in people who have certain health conditions, such as a weakened immune system, skin conditions like eczema or other exfoliative skin conditions, or pregnancy.
  • No data are available yet on the effectiveness of these vaccines in the current outbreak.
  • The immune response takes 14 days after the second dose of JYNNEOS and 4 weeks after the ACAM2000 dose for maximal development. People who get vaccinated should continue to take steps to protect themselves from infection by avoiding close, skin-to-skin contact, including intimate contact, with someone who has monkeypox.
  • To better understand the protective benefits of these vaccines in the current outbreak, CDC will collect data about adverse events and vaccine effectiveness, including whether the vaccine protects a person differently depending on how they were infected with Monkeypox virus.

August 1, 2022 - Posted by | Deception | ,

No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.